A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer
Abstract
What is this summary about?
Dostarlimab, also known by the brand name JEMPERLI, is a medicine that can be used to treat certain types of endometrial cancer. GARNET is an ongoing phase 1 clinical study that is testing the safety and side effects of dostarlimab and the best way to administer it to patients. The results presented in this summary are from a time point in the middle of the study.
What were the results?
The results from the GARNET study published in 2022 showed how well dostarlimab worked for people participating in the study. Dostarlimab was found to reduce the size of tumors in patients with certain types of endometrial cancer. The patients treated with dostarlimab had side effects that could be managed and few severe side effects.
What do the results mean?
The results of the GARNET study led to dostarlimab being approved to treat patients with certain types of endometrial cancer. For patients with advanced-stage endometrial cancer, or endometrial cancer that has come back after chemotherapy (recurrent), there are few treatment options. The results suggest that dostarlimab may provide long-term benefits for these patients.
This is an abstract of the Plain Language Summary of Publication article.
To read the full Plain Language Summary of this article, click here to view the PDF.
Link to original article here
Financial & competing interests disclosure
This study (NCT02715284) was funded by GSK. Trademarks are owned by or licensed to the GSK group of companies. Full author disclosure information can be found in the original article.
Writing and editorial support, funded by GSK (Waltham, MA, USA) was provided by Sandra B. Munro, PhD, Nicole Renner, PhD, and Dena McWain, BA, of Ashfield MedComms, an Inizio company.
Open access
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
